Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fertility Market Poised For Growth Spurt After Fallow Decade

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Late-stage pipeline is dominated by follicle stimulating hormones, split between “biobetters” and biosimilars. Next-generation oxytocin antagonists are leading candidates for the next novel entities in infertility.

You may also be interested in...



Drug Approval Briefs: Cubist, Iroko, Merck Serono, UCB, Genentech, Allergan, GE Healthcare, Zogenix

UCB’s Cimzia wins ankylosing spondylitis claim, but axial spondyloarthritis is not looking good; GE’s Vizamyl joins Amyvid on list of underemployed amyloid imagers; Cubist stretches Entereg label a bit; Iroko builds a safer NSAID; and more.

Using Quantified-Self Data To Enhance Fertility And Pregnancy

Women trying to get pregnant are seeking personalized, accurate, actionable information about fertility, and health IT and medtech start-ups are answering this need via the power of data. Profiles of Fertility Focus, OvuLine, and Univfy.

Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?

Halfway through the first year of the biosimilar user fee program, fee payments have not lived up to the expectation in President Obama’s FY 2013 budget request. Initial meetings continue to grow but at a slow pace, suggesting sponsors may remain hesitant about the pathway.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel